相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment
Ciaran James Mooney et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Renal cell carcinoma
James J. Hsieh et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Distinct routes of lineage development reshape the human blood hierarchy across ontogeny
Faiyaz Notta et al.
SCIENCE (2016)
The many faces of hematopoietic stem cell heterogeneity
Mihaela Crisan et al.
DEVELOPMENT (2016)
Flt3 Ligand Regulates the Development of Innate Lymphoid Cells in Fetal and Adult Mice
Anne Baerenwaldt et al.
JOURNAL OF IMMUNOLOGY (2016)
Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype
T. A. Mueller et al.
LEUKEMIA (2016)
Permissive roles of cytokines interleukin-7 and Flt3 ligand in mouse B-cell lineage commitment
Lilly von Muenchow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Hematopoietic stem cells: concepts, definitions, and the new reality
Connie J. Eaves
BLOOD (2015)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Ahmad Antar et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Murine germinal center B cells require functional Fms-like tyrosine kinase 3 signaling for IgG1 class-switch recombination
Mattias N. D. Svensson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Instruction of hematopoietic lineage choice by cytokine signaling
Max Endele et al.
EXPERIMENTAL CELL RESEARCH (2014)
F1t3 signaling regulates the proliferation, survival, and maintenance of multipotent hematopoietic progenitors that generate B cell precursors
Joseph J. Dolence et al.
EXPERIMENTAL HEMATOLOGY (2014)
Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells
Anna E. Beaudin et al.
EXPERIMENTAL HEMATOLOGY (2014)
In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development
Panagiotis Tsapogas et al.
HAEMATOLOGICA (2014)
Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate
Amit Grover et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The biology and targeting of FLT3 in pediatric leukemia
Colleen E. Annesley et al.
FRONTIERS IN ONCOLOGY (2014)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
SLAM Family Markers Resolve Functionally Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors
Hideyuki Oguro et al.
CELL STEM CELL (2013)
A Clonogenic Progenitor with Prominent Plasmacytoid Dendritic Cell Developmental Potential
Nobuyuki Onai et al.
IMMUNITY (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
M-CSF instructs myeloid lineage fate in single haematopoietic stem cells
Noushine Mossadegh-Keller et al.
NATURE (2013)
FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice
Emily Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors
Adam J. Mead et al.
CELL REPORTS (2013)
FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm
S. Haihua Chu et al.
CELL STEM CELL (2012)
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia
M. Hofmann et al.
LEUKEMIA (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential
Sidinh Luc et al.
NATURE IMMUNOLOGY (2012)
Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells
Natalija Buza-Vidas et al.
BLOOD (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
All Hematopoietic Cells Develop from Hematopoietic Stem Cells through Flk2/Flt3-Positive Progenitor Cells
Scott W. Boyer et al.
CELL STEM CELL (2011)
Integration of cytokine and transcription factor signals in hematopoietic stem cell commitment
Sandrine Sarrazin et al.
SEMINARS IN IMMUNOLOGY (2011)
Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
Perry M. Chan
PROTEIN & CELL (2011)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity
Robert Mansson et al.
BLOOD (2010)
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy
Jinshui Fan et al.
BLOOD (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Flt3 ligand-receptor interaction is important for maintenance of early thymic progenitor numbers in steady-state thymopoiesis
Linda Kenins et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Interleukin-7-induced Stat-5 Acts in Synergy with Flt-3 Signaling to Stimulate Expansion of Hematopoietic Progenitor Cells
Josefine Ahsberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RNA Interference Screen in Primary Human T Cells Reveals FLT3 as a Modulator of IL-10 Levels
Anne L. Astier et al.
JOURNAL OF IMMUNOLOGY (2010)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment
Lee Kim Swee et al.
BLOOD (2009)
Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development
Matthew A. Inlay et al.
GENES & DEVELOPMENT (2009)
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Chunaram Choudhary et al.
MOLECULAR CELL (2009)
In Vivo Analysis of Dendritic Cell Development and Homeostasis
Kang Liu et al.
SCIENCE (2009)
Hematopoietic Cytokines Can Instruct Lineage Choice
Michael A. Rieger et al.
SCIENCE (2009)
Models of haematopoiesis: seeing the wood for the trees
Rhodri Ceredig et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Down-regulation of Mpl marks the transition to lymphoid-primed multipotent progenitors with gradual loss of granulocyte-monocyte potential
Sidinh Luc et al.
BLOOD (2008)
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
Li Li et al.
BLOOD (2008)
Flk2+ common lymphoid progenitors possess equivalent differentiation potential for the B and T lineages
Holger Karsunky et al.
BLOOD (2008)
FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis
Christina T. Jensen et al.
BLOOD (2008)
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Annahita Sallmyr et al.
BLOOD (2008)
Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis
Sina Koch et al.
CELLS TISSUES ORGANS (2008)
Intrathymic expression of Flt3 ligand enhances thymic recovery after irradiation
Linda Kenins et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The receptor tyrosine kinase FIt3 is required for dendritic cell development in peripheral lymphoid tissues
Claudia Waskow et al.
NATURE IMMUNOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
Critical role of FLT3 ligand in IL-7 receptor-independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors
Ewa Sitnicka et al.
BLOOD (2007)
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
Benjamin H. Lee et al.
CANCER CELL (2007)
Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy
Natalija Buza-Vidas et al.
BLOOD (2007)
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1
Axel Kallies et al.
IMMUNITY (2007)
Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation
Evert-Jan Wils et al.
JOURNAL OF IMMUNOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment
Rhodri Ceredig et al.
BLOOD (2006)
Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment
ML Holmes et al.
GENES & DEVELOPMENT (2006)
Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development
N Onai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model
BH Lee et al.
ONCOGENE (2005)
Frontline:: A B220+ CD117+ CD19- hematopoietic progenitor with potent lymphoid and myeloid developmental potential
G Balciunaite et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
MJ Kiel et al.
CELL (2005)
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
C Choudhary et al.
BLOOD (2005)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
Cutting edge:: Generation of splenic CD8+ and CD8- dendritic cell equivalents in fms-like tyrosine kinase 3 ligand bone marrow cultures
SH Naik et al.
JOURNAL OF IMMUNOLOGY (2005)
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential:: A revised road map for adult blood lineage commitment
J Adolfsson et al.
CELL (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins
B Scheijen et al.
ONCOGENE (2004)
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression
R Zheng et al.
BLOOD (2004)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
K Ozeki et al.
BLOOD (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
NJ Lacayo et al.
BLOOD (2004)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
R Zheng et al.
BLOOD (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo
H Karsunky et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
Conditional expression of murine Flt3 ligand leads to expansion of multiple dendritic cell subsets in peripheral blood and tissues of transgenic mice
DJ Manfra et al.
JOURNAL OF IMMUNOLOGY (2003)
STAT3 is required for FIM-dependent dendritic cell differentiation
Y Laouar et al.
IMMUNITY (2003)
Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs
P Brawand et al.
JOURNAL OF IMMUNOLOGY (2002)
Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool
E Sitnicka et al.
IMMUNITY (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
LM Kelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
FIG ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers
ML Disis et al.
BLOOD (2002)
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
H Kiyoi et al.
ONCOGENE (2002)
The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor
M Gilliet et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice
M O'Keeffe et al.
BLOOD (2002)
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
LM Kelly et al.
BLOOD (2002)
Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells
JL Christensen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Upregulation of flt3 expression within the bone marrow Lin-Sca1+c-kit+ stem cell compartment is accompanied by loss of self-renewal capacity
J Adolfsson et al.
IMMUNITY (2001)
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
L Fong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
Flt3 ligand induces tyrosine phosphorylation of Gab1 and Gab2 and their association with Shp-2, grb2, and P13 kinase
SL Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Polyethylene glycol-modified GM-CSF expands CD11bhighCD11chigh but not CD11blowCD11chigh murine dendritic cells in vivo:: A comparative analysis with Flt3 ligand
E Daro et al.
JOURNAL OF IMMUNOLOGY (2000)
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
K Akashi et al.
NATURE (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
分享论文
